REFERENCES
- Honeker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21: 42–7.
- Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9–17.
- Uhm JH, Yung WK. Neurologic complications of cancer therapy. Curr Treat Options Neurol 1999; 1: 428–37.
- Hilkens PH, van den Bent MJ. Chemotherapy-induced periph-eral neuropathy. J Peripher Nerv Syst 1997; 2: 350–61.
- Morgan E. Chemotherapy-induced neurotoxicity. Cancer Con-trol 1995; 2: 235–42.
- Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin 1991; 9: 955–67.
- Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progres-sive paraesthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 1989; 25: 62–4.
- Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurolo-gic tissue, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795–803.
- Connelly E, Markman M, Kennedy A. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecological cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996; 62: 166–8.
- Rose PG, Blessing JA, Gershenson DM, McGehee R. Pacli-taxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncol-ogy Group study. J Clin Oncol 1999; 17: 2676–80.
- Rowinski EK, Chaudhry V, Cornblath DR, Donehower RC. The neurotoxicity of taxol. Monogr Natl Cancer Inst 1993; 15: 107.
- Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002; 41: 418–24.
- Chaudhry V, Rowinski EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35: 304–11.
- Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 60–7.
- Pace A, Bove L, Nistic6 C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996; 61: 409–11.
- Dittrich C, Zifko U, Fazeny B, Fielg M, Grisod W, Huber H. Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity? Ann Oncol 1994; 5: 473–4.
- Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: a phase II study. Cancer Chemother Pharmacol 1996; 39: 150–6.
- Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996; 88: 1079–80.
- Ji-Youn H, Byung Gil GC, Dae Heon S, Jae Geun A, Jeong-Seob Y, Kyung Shik L. Vinorelbine-associated myelopathy in a patient who previously received paclitaxel. Med Oncol 2001; 18: 95–7.